Court says OxyContin maker's bankruptcy and protections for Sackler family members can move ahead
OxyContin maker Purdue Pharma can start its transformation under a bankruptcy agreement that allows the members of the wealthy Sackler family who own the company to avoid civil lawsuits over the opioid crisis, a court has ruled
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.OxyContin maker Purdue Pharma can start executing a settlement that protects members of the Sackler family who own the company from civil lawsuits over the toll of opioids, a court ruled Tuesday.
The ruling from the 2nd U.S. Circuit Court of Appeals in New York allows the company's transformation to start.
Under a deal reached last year with thousands of state and local government entities, the company is to become a new entity with its profits being used to fight the opioid epidemic. And Sackler family members are to pay up to $6 billion over time.
The Purdue deal is one of the bigger ones in a series of corporate opioid settlements worth a total of more than $50 billion so far. Unlike most of them, it includes funds for people who were victims of the crisis and their families.
In exchange, the members of the wealthy Sackler family, who are not themselves seeking bankruptcy protections, are to be shielded from lawsuits.
A 2nd Circuit panel approved the deal in May. By then, the main remaining objector was the U.S. Bankruptcy Trustee, which says the Sacklers should not have legal protections.
The trustee has said in court filings that it intends to ask the U.S. Supreme Court to take the case. The deadline for that request is Aug. 28.
But the 2nd Circuit said Tuesday that it would not hold back the settlement from being enacted. The bankruptcy trustee could now ask the top court to put the settlement plan on hold.
The trustee, an arm of the federal Department of Justice, did not immediately respond to an email seeking comment Tuesday. Purdue Pharma didn’t immediately comment.
The trustee warned the 2nd Circuit in the filing that if it did not keep Purdue's transformation on hold, it might be too late, saying in a filing that “the plan proponents will act swiftly to consummate the plan” in an effort to make the objections moot.
Opioids have been linked to more than 70,000 fatal overdoses annually in the U.S. in recent years. Most of those are from fentanyl and other synthetic drugs, but the crisis widened in the early 2000s as OxyContin and other powerful prescription painkillers became prevalent.